In the study, published in the journal Pharmaceutics, the molecules the researchers used to bind the chemical structure of insulin, called AAC2, were developed in the lab of study co-author John Parquette, also a professor of chemistry and biochemistry.
According to the study findings, they think such benefits are related to how insulin’s interactions with the nanomaterial affect two aspects of glucose utilization in the body, including glucose for energy metabolism and glucose utilization for both structural and storage needs.
Researchers at Ohio State University have developed a new technology combining insulin and self-assembling amino acid compounds (AACs) to address cognitive diseases associated with diabetes. This nanomaterial could be adapted for other metabolic and neurological disorders.
 Morales, Marie. “Nanomaterial for Better Insulin Effects; New Approach to Effectively Treat Type 1 & 2 Diabetes.” Science Times, 30 Mar. 2022, www.sciencetimes.com/articles/36890/20220330/nanomaterial-better-insulin-effects-new-approach-effectively-treat-type-1.htm
 Lee, Aejin, et al. “Amino Acid Nanofibers Improve Glycemia and Confer Cognitive Therapeutic Efficacy to Bound Insulin.” Pharmaceutics, vol. 14, no. 1, Dec. 2021, p. 81, https://doi.org/10.3390/pharmaceutics14010081